Identification of 9-O-acetyl-N-acetylneuraminic acid (Neu5,9Ac2) as main O-acetylated sialic acid species of GD2 in breast cancer cells

Cavdarli, Sumeyye; Dewald, Justine H.; Yamakawa, Nao; Guérardel, Yann; Terme, Mickaël; Doussal, Jean-Marc Le; Delannoy, Philippe; Groux-Degroote, Sophie

doi:10.1007/s10719-018-09856-w

Cited by 42 publications

(53 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Ganglioside overexpression in cancer has been reported such as CNS-specific GD3s from tumor tissues [355]. The overexpression of 9-O-acetylated sialic acid in BC [356], childhood ALL [83,[103][104][105][106][107] are reported.…”

Section: Sialylation and Diseasementioning

confidence: 98%

“…O-acetylation of disialoganglioside GD3 by human melanoma cells has been reported to be a unique antigenic determinant [109]. BC cells have recently been reported to express b-series gangliosides GD3 and GD2, and O-acetylated GD2 (O-AcGD2) in which 9-O-acetyl-N-acetylneuraminic acid (Neu5,9Ac 2 ) is predominant O-acetylated sialic acid species of GD2 [110].…”

Section: Functions Of O-acetylated Sialic Acidsmentioning

confidence: 99%

See 1 more Smart Citation

Sialic acid and biology of life: An introduction

Ghosh¹

2020

Sialic Acids and Sialoglycoconjugates in the Biology of Life, Health and Disease

View full text Add to dashboard Cite

Section: Sialylation and Diseasementioning

confidence: 98%

Section: Functions Of O-acetylated Sialic Acidsmentioning

confidence: 99%

Sialic acid and biology of life: An introduction

Ghosh¹

2020

Sialic Acids and Sialoglycoconjugates in the Biology of Life, Health and Disease

View full text Add to dashboard Cite

“…Some of the anti-ganglioside antibodies are known for recognizing the O-acetylated form of the targeted gangliosides. For example, anti-GD2 14.18 antibody can also recognize the O-acetylated GD2 species with a lower affinity compared to its preferential target GD2 [66]. Furthermore, antibodies targeting O-acetylated gangliosides can also cross react, such as 493D4 [67], Jones antibody [68] or A2B5 [69], targeting both OAcGD3/OAcGT3 and OAcGT2.…”

Section: Analysis Of O-acetylated and Non-o-acetylated Gangliosides Smentioning

confidence: 99%

“…Furthermore, antibodies targeting O-acetylated gangliosides can also cross react, such as 493D4 [67], Jones antibody [68] or A2B5 [69], targeting both OAcGD3/OAcGT3 and OAcGT2. In turn, the specificity of anti-OAcGD2 8B6 mAb has been demonstrated by several immunodetection methods, with no 8B6 binding after the removal of the O-acetyl group by alkali-based treatment [66,[70][71][72]. Recently, gangliosides expressed by neuroectoderm-derived cancer cells have been profiled using MALDI-TOF analysis on native gangliosides.…”

Section: Analysis Of O-acetylated and Non-o-acetylated Gangliosides Smentioning

confidence: 99%

O-acetylated Gangliosides as Targets for Cancer Immunotherapy

Cavdarli

Delannoy

Groux-Degroote

2020

Cells

Self Cite

View full text Add to dashboard Cite

O-acetylation of sialic acid residues is one of the main modifications of gangliosides, and modulates ganglioside functions.O-acetylation of gangliosides is dependent on sialyl-O-acetyltransferases and sialyl-O-acetyl-esterase activities. CAS1 Domain-Containing Protein 1 (CASD1) is the only human sialyl-O-acetyltransferases (SOAT) described until now. O-acetylated ganglioside species are mainly expressed during embryonic development and in the central nervous system in healthy adults, but are re-expressed during cancer development and are considered as markers of cancers of neuroectodermal origin. However, the specific biological roles of O-acetylated gangliosides in developing and malignant tissues have not been extensively studied, mostly because of the requirement of specific approaches and tools for sample preparation and analysis. In this review, we summarize our current knowledge of ganglioside biosynthesis and expression in normal and pathological conditions, of ganglioside O-acetylation analysis and expression in cancers, and of the possible use of O-acetylated gangliosides as targets for cancer immunotherapy. a potential functional significance of ganglioside O-acetylation in cancer. The use of O-acetylated gangliosides as targets for cancer immunotherapy is also discussed. Ganglioside Structures and BiosynthesisGangliosides are acidic GSL containing from one to five sialic acids residues. They are mainly, but not exclusively, derived from ganglio-series GSL (GgCer) that result from the substitution of a ceramide (Cer) by the tetrasaccharide core Galβ1-3GalNAcβ1-4Galβ1-4Glcβ (Gg4). In different cell types and tissues, gangliosides are usually found as a mixture of di-, tri-and tetrasaccharide cores substituted by one or more sialic acid residues [1,5]. The biosynthesis of gangliosides takes place in the Golgi apparatus and starts by the transfer of sialic acid residues to lactosylceramide (LacCer) by specific sialyltransferases, i.e., the CMP-Neu5Ac: LacCer α2,3-sialyltransferase ST3Gal V (GM3 synthase) [6], the CMP-Neu5Ac: GM3 α2,8-sialyltransferase ST8Sia I (GD3 synthase) [7] and the CMP-Neu5Ac: GD3 α2,8-sialyltransferase ST8Sia V [8], that show high specificity toward glycolipid substrates [9]. Thus, LacCer, GM3, GD3 and GT3 are the precursors for 0-, a-, b-and c-series gangliosides, respectively (Figure 1).

show abstract

“…The complex ganglioside GD2 is expressed on tumours of neuroectodermal origin and has a key role in the aggressiveness of some cancers including neuroblastoma and melanoma. GD2 can be inhibited with monoclonal antibodies and holds major potential as a target for cancer therapy [52,60]. The anti-GD2 monoclonal antibody dinutuximab can help improve survival in patients with high-risk neuroblastoma.…”

Section: Cancer-associated Sialyloglycansmentioning

confidence: 99%

Targeting Aberrant Sialylation to Treat Cancer

Munkley

Scott

2019

Medicines

View full text Add to dashboard Cite

Cell surface carbohydrates (known as glycans) are often aberrantly expressed or found at atypical levels in cancer. Glycans can impact all steps in tumour progression, from malignant transformation to metastasis, and have roles in all the cancer hallmarks. An increased understanding of glycans in the metastatic cascade offers exciting new therapeutic opportunities. Glycan-based targeting strategies are currently being tested in clinical trials and are a rich and untapped frontier for development. As we learn more about cancer glycobiology, new targets will continue to emerge for drug design. One key change in tumour glycosylation is the upregulation of cancer-associated sialylated glycans. Abnormal sialylation is integral to tumour growth, metastasis and immune evasion; therefore, targeting sialic acid moieties in cancer could be of high therapeutic value. Here, we summarise the changes to sialic acid biology in cancer and discuss recent advances and technologies bringing sialic-acid targeting treatments to the forefront of cancer therapeutics.

show abstract

Identification of 9-O-acetyl-N-acetylneuraminic acid (Neu5,9Ac2) as main O-acetylated sialic acid species of GD2 in breast cancer cells

Cited by 42 publications

References 36 publications

Sialic acid and biology of life: An introduction

Sialic acid and biology of life: An introduction

O-acetylated Gangliosides as Targets for Cancer Immunotherapy

Targeting Aberrant Sialylation to Treat Cancer

Contact Info

Product

Resources

About